A Study of Sterile Saline Infusion in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Other: Sterile Saline
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06194578
- Locations
- πΊπΈ
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
A Study of JNJ-87890387 for Advanced Solid Tumors
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 158
- Registration Number
- NCT06178614
- Locations
- πͺπΈ
Hosp Univ Vall D Hebron, Barcelona, Spain
πΊπΈStart Midwest, Grand Rapids, Michigan, United States
π«π·Centre Leon Berard, Lyon, France
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
- Conditions
- NeoplasmsMyelofibrosisEssential ThrombocythemiaMyeloproliferative Disorders
- Interventions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06150157
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
πΊπΈMoffit Cancer center, Tampa, Florida, United States
πΊπΈUniversity of Michigan, Ann Arbor, Michigan, United States
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: JNJ-77242113 Matching Placebo
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 774
- Registration Number
- NCT06143878
- Locations
- ππΊ
SZTE AOK Szent-Gyorgyi Albert Klinikai Kozpont, Borgyogyaszati Γ©s Allergologiai Klinika, Szeged, Hungary
ππΊAllergo-Derm Bakos Kft., Szolnok, Hungary
ππΊMedmare Egeszsegugyi Es Szolgaltato Bt., Veszprem, Hungary
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 235
- Registration Number
- NCT06139406
- Locations
- π¦πΊ
Austin Hospital, Heidelberg, Australia
π¦πΊThe Alfred Hospital, Melbourne, Australia
π¦πΊLinear Clinical Research Ltd, Nedlands, Australia
A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
- Conditions
- Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 959
- Registration Number
- NCT06134804
- Locations
- π΅π±
Synexus Polska Sp z o o Oddzial w Katowicach, Katowice, Poland
πΊπΈMedical Affiliated Research Center Inc. (MARC), Huntsville, Alabama, United States
πΊπΈAlliance for Multispeciality Research, Knoxville, Tennessee, United States
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: Amivantamab IVDrug: Amivantamab SCOther: Noncomedogenic skin moisturizerOther: RuxolitinibOther: Tacrolimus
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06120140
- Locations
- πΉπ·
Adana City Hospital, Adana, Turkey
πΉπ·Gulhane Training and Research Hospital, Ankara, Turkey
π¨π³Sichuan Cancer Hospital, Chengdu, China
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 311
- Registration Number
- NCT06095102
- Locations
- πΊπΈ
California Dermatology & Clinical Research Institute, Encinitas, California, United States
πΊπΈForcare Clinical Research Inc, Tampa, Florida, United States
πΊπΈHamilton Research LLC, Alpharetta, Georgia, United States
A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
- Conditions
- Advanced Prostate Cancer
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06095089
- Locations
- πΊπΈ
South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas, United States
π«π·Centre Leon Berard, Lyon, France
πΊπΈUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 684
- Registration Number
- NCT06095115
- Locations
- πΊπΈ
Medical Dermatology Specialists, Phoenix, Arizona, United States
πΊπΈJohnson Dermatology, Fort Smith, Arkansas, United States
πΊπΈFirst OC Dermatology, Fountain Valley, California, United States